DaeWoong Pharmaceutical Announces Positive Safety Review for Bersiporocin
DaeWoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin (DWN12088) received a recommendation to continue its global Phase 2 clinical trial following a positive safety review by the third Independent Data Monitoring Committee (IDMC) held on September 23.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
- 94 patients enrolled out of 102 planned across Korea and the U.S.
- The study is progressing as planned, with approximately 92% of the target population enrolled.
Author's summary: Daewoong Pharmaceutical's Bersiporocin clinical trial continues after positive safety review.